Weight Loss Injections 2026: Complete Guide to GLP-1s, Tirzepatide & Beyond

Prescription injections have expanded the options for treating obesity. Compare semaglutide, tirzepatide, and liraglutide, then explore the emerging evidence for retatrutide and AOD-9604. This guide covers trial results, dosing, side effects, costs, and access, with a clear distinction between established treatments and investigational peptides.

The Weight Loss Injection Revolution

Brand and indication matter: Wegovy, Zepbound, and Saxenda have weight-management indications; Ozempic and Mounjaro have diabetes-focused labels. Their doses, devices, and insurance pathways differ. See the Wegovy, Zepbound, Saxenda, Ozempic, and Mounjaro prescribing information.

Key facts:

• Compare the actual dose, trial population, and duration, not just a headline weight-loss percentage.
• A direct comparison, such as SURMOUNT-5 below, answers a different question from comparing separate trials.
• Retatrutide has phase 3 human evidence; AOD-9604 has a much less established weight-loss evidence base.
• Primary care, obesity-medicine clinics, and telehealth offer different ways to access assessment and follow-up.
• Compare ongoing medication costs plus any membership fees, not just introductory prices.

Comprehensive Comparison of All Weight Loss Injections

These are separate trial averages, not a head-to-head ranking. The obesity studies shown enrolled adults without diabetes; minus signs indicate weight loss. US prices checked October 9, 2026, exclude separate service fees. For Wegovy and Ozempic, the eligible $199 introduction covers each of the first two 0.25/0.5 mg monthly fills for patients new to the Savings Offer/NovoCare Pharmacy, through December 31, 2026. Zepbound figures are regular KwikPen self-pay prices, not single-dose pen prices. Mounjaro savings depend on commercial coverage. Check a pharmacy for Saxenda pricing and availability. More offer details follow below.

Primary results: STEP 1, SURMOUNT-1, SCALE, and TRIUMPH-1. Diabetes-brand rows are kept separate from obesity-brand estimates; SURPASS-2 was a 40-week type 2 diabetes trial with HbA1c as its primary outcome.

Semaglutide (Ozempic, Wegovy, Rybelsus)

Wegovy has weight-management indications and both injectable and oral forms; this guide covers injections. Ozempic injection has type 2 diabetes indications, including cardiovascular or kidney benefits in specified populations. Rybelsus is oral. See the Wegovy label and Ozempic label.

Mechanism: Semaglutide reduces calorie intake through appetite effects (Wegovy pharmacology). Its glucose-dependent insulin and gastric-emptying effects are described in Ozempic pharmacology.

Adult Wegovy injection dosing: 0.25 mg weekly (weeks 1–4), 0.5 mg (weeks 5–8), 1 mg (weeks 9–12), then 1.7 mg (weeks 13–16). Maintenance starts at week 17: 2.4 mg recommended, or 1.7 mg. If needed, 7.2 mg follows at least 4 weeks tolerating 2.4 mg. Prescribers may delay escalation for tolerability. See the dosing instructions.

Trial evidence: In STEP 1, 1,961 adults without diabetes received semaglutide 2.4 mg or placebo with lifestyle support for 68 weeks; mean weight change was −14.9% versus −2.4%. A separate STEP-UP trial in 1,407 adults without diabetes reported treatment-policy changes of −18.7%, −15.6%, and −3.9% at 72 weeks for 7.2 mg, 2.4 mg, and placebo. Neither result is a promise for an individual or a direct comparison with tirzepatide. Read the STEP 1 report, STEP-UP report, and STEP 1 extension for the separate one-year follow-up.

Injection costs: After the eligible introduction, Wegovy's offer is $349 per four-pen month for 0.25–2.4 mg, or $399 for 7.2 mg HD. Ozempic's offer is $349 per one-pen month for 0.25/0.5/1 mg or $499 for 2 mg. Eligibility restrictions apply; offers can change.

Tirzepatide (Mounjaro, Zepbound)

Tirzepatide is a dual GLP-1/GIP receptor agonist. Zepbound is the weight-management product; Mounjaro is labeled for type 2 diabetes and specified cardiovascular-risk reduction in high-risk adults with type 2 diabetes. See the Zepbound label and Mounjaro label.

Mechanism: Tirzepatide acts at both GIP and GLP-1 receptors, reducing calorie intake and affecting glucose-dependent insulin secretion. See the Mounjaro pharmacology section.

Dosing for weight loss (Zepbound): Start at 2.5 mg weekly for 4 weeks, then 5 mg. If needed, increase by 2.5 mg only after at least 4 weeks at the current dose, including 7.5 mg, 10 mg, and 12.5 mg before 15 mg. Maintenance may be 5, 10, or 15 mg based on response and tolerability; not everyone must reach 15 mg. See the prescribing instructions.

Trial evidence: In SURMOUNT-1, 2,539 adults without diabetes received 5, 10, or 15 mg for 72 weeks including escalation; mean changes were −15.0%, −19.5%, and −20.9% versus −3.1% with placebo. In the open-label SURMOUNT-5 trial, 751 adults with obesity without type 2 diabetes received maximum-tolerated tirzepatide 10 or 15 mg or semaglutide 1.7 or 2.4 mg for 72 weeks; mean change was −20.2% versus −13.7%. This directly favored tirzepatide at the studied doses, but did not compare 7.2 mg semaglutide. Read SURMOUNT-1 and SURMOUNT-5.

Diabetes-trial context: SURPASS-2 studied 1,879 people with type 2 diabetes for 40 weeks, comparing tirzepatide 5/10/15 mg with semaglutide 1 mg. HbA1c was the primary outcome. This population and comparator differ from the obesity trials above. Read the SURPASS-2 report. Both medicines are weekly injections; see the KwikPen pricing terms and detailed savings conditions below.

Liraglutide (Saxenda, Victoza)

Liraglutide is a GLP-1 receptor agonist. Saxenda is the weight-management product; Victoza is a diabetes product. That distinction matters when discussing indication and coverage. See the Saxenda label.

Mechanism and schedule: Liraglutide acts at the GLP-1 receptor. Saxenda uses daily injections.

Adult dosing: Saxenda starts at 0.6 mg daily in week 1, then increases weekly to 1.2 mg, 1.8 mg, 2.4 mg, and 3 mg from week 5. Lower doses are for escalation. Discontinue if 3 mg is not tolerated or weight loss is below 4% at 16 weeks, according to the prescribing instructions.

Trial evidence: In SCALE, 3,731 adults without type 2 diabetes received liraglutide 3 mg or placebo with lifestyle support for 56 weeks. The original report found mean losses of 8.4 kg versus 2.8 kg, using last-observation-carried-forward analysis. Read the SCALE report.

Cost and availability: Ask a pharmacy for a current quote. Novo Nordisk plans its last Saxenda shipments to wholesalers in late January 2027, describing a portfolio decision unrelated to safety or quality. Discuss availability and alternatives with your clinician; this is advance notice, not immediate withdrawal. See the manufacturer's notice.

Retatrutide (Emerging Triple Agonist)

Retatrutide is an investigational triple agonist of GIP, GLP-1, and glucagon receptors. It is being studied as a potential additional treatment for obesity.

Trial data: TRIUMPH-1 randomized 2,339 adults with obesity without diabetes for 80 weeks. In the 12 mg group, the published treatment-regimen/intent-to-treat result was −25.0% mean weight change versus −3.9% with placebo. Gastrointestinal events were reported; longer-term and comparative evidence remain under study. Read the TRIUMPH-1 report.

Status and cost: Retatrutide is investigational, not FDA-approved, and not a generally available commercial prescription. The sponsor describes clinical-trial access, with no announced commercial price or confirmed launch date. See the sponsor's retatrutide status page.

AOD-9604 and Other Emerging Peptides

AOD-9604 is the modified growth-hormone fragment Tyr-hGH 177–191, not a growth-hormone-releasing secretagogue. Animal fat-metabolism findings motivated human research. A company-affiliated 2013 report summarized six intravenous or oral trials, reporting tolerability and no increase in IGF-1; it did not establish subcutaneous weight-loss efficacy or long-term safety. Read the human report.

Human weight-loss evidence: An early oral study reported limited signals, but the larger oral OPTIONS trial, with 502 people randomized, missed its primary weight-loss endpoint. The 2024 FDA evidence briefing describes these results and the lack of identified subcutaneous exposure data. The oral findings cannot establish how well an injected product works.

Emerging and anecdotal use: AOD-9604 remains a research topic rather than a validated prescription weight-management option. Anecdotes about combining it with GLP-1 medicines are hypothesis-generating, not evidence of additional benefit; controlled combination data are needed.

Cost: There is no established prescription weight-loss regimen on which to base a comparable monthly medication price.

How Weight Loss Injections Work: The Biology

This overview concerns GLP-1-based medicines, not every peptide. See the pharmacology sections of the Wegovy, Ozempic, and Mounjaro labels:

1. Appetite and intake: Effects on appetite regulation can reduce hunger and calorie intake.

2. Gastric emptying: Semaglutide and tirzepatide delay gastric emptying; the effect is largest after the first dose and diminishes over time for tirzepatide.

3. Glucose-dependent signaling: Insulin secretion increases when blood glucose is elevated, supporting glucose control.

4. Energy balance: Lower calorie intake is different from a proven rise in resting metabolic rate. The amount of weight lost also depends on dose, duration, and individual response.

5. Gut-brain signaling: Brain GLP-1 receptors help regulate appetite.

Factors Affecting Weight Loss Efficacy

Not everyone loses the same amount on the same medication. Several factors shape response:

• Baseline weight: Percent change and absolute pounds answer different questions; baseline weight alone does not predict an individual's result.
• Adherence and tolerability: Missed doses, adverse effects, and dose delays can change exposure and the pace of escalation.
• Trial population: Diabetes status, eligibility, comparator, and follow-up duration limit how results transfer to another person or product.
• Nutrition, activity, and sleep: Build these into the care plan alongside medication and follow-up.
• Individual response: Track your own progress and symptoms with the prescriber rather than treating a trial average as a personal target.
• Dose and duration: A higher tolerated dose can produce a different trial average, while continued treatment and follow-up influence maintenance.

Side Effects Comparison

Separate adult trial pools, not a head-to-head comparison: Wegovy 2.4 mg, 2,116 treated/1,261 placebo; Zepbound 5/10/15 mg, 630/948/941 treated/958 placebo, including a diabetes trial; Saxenda 3 mg, 3,384 treated/1,941 placebo. Zepbound ranges span doses, not confidence intervals. The Wegovy column is not the 7.2 mg pool.

These products are contraindicated with a personal/family history of medullary thyroid carcinoma or MEN2. Discuss pregnancy plans and other medications with your prescriber. Persistent severe abdominal pain or allergic breathing difficulty/facial swelling needs urgent care. See the product labels linked above.

How to Get Weight Loss Injections

Option 1: Traditional Doctor Visit

A primary-care clinician or obesity-medicine specialist can review your goals, medical history, current medicines, and eligibility, order tests when needed, and plan treatment and follow-up.

Option 2: Telehealth GLP-1 Services

Services such as Ro, Hims, Noom, and WeightWatchers offer remote evaluation. Compare clinician access, follow-up, pharmacy, and separate charges. As of October 9, 2026, Ro's monthly-plan membership is $39 for the first month, then $149/month, plus medication; lower monthly equivalents require prepayment. A prescription depends on clinical suitability.

Option 3: Weight Loss Clinics

Specialized weight-management centers may combine prescribing, nutrition counseling, and follow-up. Ask for the exact consultation, membership, medication, and device charges rather than relying on an all-in estimate.

Option 4: Compounding Pharmacies

Patient-specific compounding can address a need not met by an approved product in some circumstances, but a compounded product is not FDA-approved or a generic equivalent. Use a licensed prescriber and pharmacy, confirm the active ingredient and concentration, and follow the exact device instructions. Read the FDA's current compounding safety communication.

Insurance Coverage and Cost Savings

Coverage varies by plan and indication:

• Diabetes indications: Ozempic and Mounjaro are diabetes-brand examples; Saxenda is a weight-management brand, not a diabetes brand. Coverage still depends on formulary, authorization, deductible, and eligibility.
• Weight management: Some plans cover Wegovy or Zepbound, while others do not. A savings card is not the same as insurance coverage.
• Without insurance: Use the official, dated terms in the comparison and ask the pharmacy or plan to confirm the exact dose, device, supply, and eligibility before assuming a price.

Zepbound offer example: Eligible 7.5–15 mg KwikPen purchases may cost $449 per 28-day, one-KwikPen supply. Continued eligibility requires a refill purchase within 45 days of the prior delivery/receipt. The linked commercial-card terms require an approved-use prescription, age 18+, US/Puerto Rico residency, commercial insurance without KwikPen coverage, and no government coverage; limits apply and savings end December 31, 2026. See the offer terms. Other devices and purchase pathways have different terms. Readers comparing ongoing care can review SurpassMD’s online weight-management program.

Mounjaro offer example: Eligible commercially insured patients without Mounjaro coverage may pay as low as $499 per 28 days, up to four single-dose pens. The card requires an approved-use prescription, age 18+, US/Puerto Rico residency, and no government coverage. Monthly/annual savings caps and fill limits apply; savings end December 31, 2026. See the Mounjaro terms. This is not a guaranteed off-label weight-loss price. Manufacturer offers can change; confirm the current total before filling.